Definitive radiotherapy and Single-Agent radiosensitizing Ifosfamide in Patients with localized, irresectable Soft Tissue Sarcoma: A retrospective analysis
© Eckert et al; licensee BioMed Central Ltd. 2010
Received: 3 March 2010
Accepted: 16 June 2010
Published: 16 June 2010
Background and Purpose
Standard therapy for soft-tissue sarcomas remains complete resection. For primary radiotherapy local control rates of 30-45% have been reported. We analyzed retrospectively 11 cases of radiochemotherapy with single-agent ifosfamide in patients with macroscopic soft-tissue sarcomas.
Patients and Methods
The patients were treated in irresectable high risk situations. Radiation therapy was performed with median 60 Gy. During the first and fifth week the concomitant chemotherapy with ifosfamide was added. Two patients received trimodal therapy with additional regional hyperthermia.
The therapy was completed in 73% of the patients. Average local control time was 91 months, median disease-free-survival/overall-survival was 8/26 months. Five-year rates for local control/disease free survival/overall survival were 70%/34%/34%. The limited prognosis is mainly caused by systemic treatment failure.
The data strongly suggest a better outcome of radiochemotherapy with ifosfamide compared to radiotherapy alone and radiotherapy in combination with other radiosensitizers.
Advanced, localized soft tissue sarcomas are still a challenge for all therapeutic disciplines involved. The multimodal therapy consists of surgery, radiotherapy and chemotherapy . Radiotherapy improves local control as neoadjuvant and adjuvant approach in many clinical situations, especially in high grade sarcomas and deep seated tumours.
Adjuvant chemotherapy is applied by some groups in selected patients with sarcomas of the extremities in high risk situations, for example deep location, grade 2 and 3 and size larger than 5 cm [2–4]. Despite all efforts, the prognosis, especially for advanced high grade sarcomas, is still limited. In localized disease the therapeutic aim is to achieve a complete resection as most important prognostic factor for local control and survival. Some authors even state that only complete, margin-negative resection can be considered as curative treatment .
The question is how to treat patients with localized, non-resectable tumours. As the disease is not metastasized, a chance for cure can be assumed, but long-term tumour control could only be achieved with radiation doses of at least 63 Gy . This dose-response-relationship reveals the difficulty of treatment, because extent of the tumour and proximity to organs at risk limit the curative approach especially in retroperitoneal sarcomas.
The first report on a series of 36 irresectable patients treated with concurrent radiochemotherapy was published in 1991. Aggressive treatment in large, irresectable soft tissue sarcoma showed to be favorable compared to the application of hypofractionated palliative regimens .
Effective chemotherapeutic regimens were initially developed for the use in metastatic disease. Considering different chemotherapeutic agents, our selection was geared to the nowadays established first-line chemotherapeutic approach consisting of anthracyclines and ifosfamide [4, 8]. Ifosfamide was chosen as radiosensitizer due to its superior toxicity profile in combination with radiotherapy [9, 10]. This treatment combination was applied in individual cases without alternative options with the informed consent of the patients, that it is no standard regimen.
The aim of our analysis was to evaluate retrospectively the safety and efficacy of simultaneous radiochemotherapy with single-agent ifosfamide. To our knowledge, this is the first approach of definitive ifosfamide-based radiochemotherapy in patients with localized, irresectable soft tissue sarcomas.
Patients and Methods
From 1996 to 2007 eleven patients (four males, seven females), median age of 55 years, were treated with concurrent ifosfamide and radiotherapy as definitive treatment primarily or after resection with gross residual tumour. Median follow-up was 55 months ranging from 4 to 131 months.
Initial tumor size
5 - 10 cm
Grade acc. FNCLCC
The diagnostic work-up included cross-sectional imaging of the tumour region and chest X-ray or computed tomography to exclude pulmonary metastasis. The tumours were diagnosed histologically. The treatment options were coordinated with all disciplines involved and surgical options were excluded. Routinely WHO (World Health Organization) performance status and laboratory parameters including creatinine clearance were assessed to ensure sufficient organ function for chemotherapy.
Radiotherapy was planned 2-D (Two-dimensional) or 3-D (Three-dimensional)-conformal. In two cases better sparing of normal tissue in the head and neck region and the retroperitoneum was achieved by IMRT (Intensity Modulated Radiotherapy). Reproducible immobilization and linear accelerators with 6-15 MV (Mega Voltage) photons were used in all patients. Median radiation dose was 60 Gy (range 50.0-72.6). Fractionation schedules were 1.8 or 2.0 Gy/day, five times a week. Two patients were treated with hyperfractionated therapy twice-daily.
Total radiation dose was aimed to be 60 Gy or higher, dose adaptations were made to achieve sparing of organs at risk. The aim was a safety margin of 2 cm in all directions. It was reduced in case of respected anatomical borders or for sparing of dose-limiting organs at risk. Accepted dose for spinal cord was 45 Gy, for small bowel 45-50 Gy and 12 Gy for at least one kidney.
Irradiation dose (Gy)
Ifosfamide dose (intended) (g/m 2 )
Additional therapy modalities
Statistical evaluation was performed with SPSS 15.0 to calculate Kaplan-Meier-plots. Local control, disease free survival and overall survival were calculated from the first day of treatment. The comparison of subgroups was done with Log-rank (Mantle-cox) test.
Radiotherapy could be applied as planned in 9/11 (82%) of patients. One patient died during therapy due to respiratory failure caused by enlarging tumour of over 20 cm in the thoracic irradiation field, compressing the lung and the great vessels. In one case radiotherapy could only be completed after a major delay of 4 weeks because of local infectious complications at the tumour site after multiple surgical procedures and osteosynthesis with revisions. The second cycle of ifosfamide was withheld in both patients and due to leucopenia CTC (Common Toxicity Criteria) grade III in one additional patient. Thus, the complete regimen was given in 8/11 (73%) of the patients. Evaluation of skin toxicity was possible for 9 of the patients, 2 of which had severe reactions CTC grade III/IV.
Individual treatment results
Initial - before RT
Total ifo dose
Toxicity ≥ °III
Local control (Mo)
Overall survival (Mo)
Skin toxicity °III
HF + HT
Death during therapy
Skin toxicity °III
RTCHX after R2-resection
15 cm - 4 cm
HF + HT
9 cm - 3 cm
6 cm - 4 cm
Leuco- penia °IV
The two patients experiencing local failure had tumours with diameters over 10 cm. The patients still at risk after 2 years all had tumours smaller than 10 cm. Thus, a trend towards better outcome for the patients with smaller tumours can be assumed.
Radiochemotherapy with single-agent ifosfamide is a feasible treatment scheme for inoperable high-risk patients with soft tissue sarcomas located in the retroperitoneum or the head and neck region.
The patients belonged to a high risk group associated with an unfavorable prognosis due to the presence of negative prognosticators in soft tissue sarcomas with respect to location, size, depth of infiltration and grading . Low grade tumours were not included. The most negative factor was irresectability respectively incomplete resection. This fact also explains the number of early death observed in 4 patients.
The use of radiosensitizing agents in patients with soft tissue sarcomas can be tracked to the late 80 ies, when for the first time aggressive treatment schedules for irresectable soft-tissue sarcomas were investigated . Goffman et al. described a better outcome and less toxicity for iododeoxyuridine compared to misonidazole. However, local control after 3 years was 37%, thus worse than the here described survival rates . Also the use of razoxane or continuous administration of doxorubicin was discussed in the 90 ies [13, 14]. Ifosfamide yielded an at least additional effect in combination with fractionated radiotherapy in a xenograft model . It was used in combined treatment regimens with multi-drug-therapy plus irradiation since 1999 [16, 17]
Radiotherapy alone yielded no local control after 5 years in retroperitoneal sarcomas . In head and neck sarcomas, individual cases (1/6 patients) demonstrated a curative potential of radiotherapy alone .
Kepka et al. described radiotherapy without additional systemic therapy in 112 patients, 33 of whom had tumours of 10 cm or more before radiotherapy (29%). 11% of the tumours were low-grade sarcomas, the rate of G3 tumours was 37%. The local control rates were 45% and 10% for tumours with diameters from 5 to 10 cm and more than 10 cm respectively after 5 years . Due to the small patient numbers no separate evaluation could be performed with our data, but the estimated overall local control rate of 70% after 5 years in a patient group with 36% of tumours greater than 10 cm and 73% high grade sarcomas gives at least indirect evidence that ifosfamide improves local control in combination with radiation therapy.
A five-year overall survival of 34% of the patients in this prognostic group thus compares favorably with historic controls of radiotherapy alone. The prognosis is determined by systemic treatment failure as 66% of the patients developed distant metastases, explaining why local control only partly translates to overall disease control. According to the latest meta-analysis concerning adjuvant chemotherapy in resected soft tissue sarcoma, an additional doxorubicin and ifosfamide-based chemotherapy regimen significantly reduced distant metastases and mortality in resected sarcomas [21, 22]. Therefore, additional adjuvant chemotherapy might further improve the outcome in patients receiving definitive radiochemotherapy as well.
The results substantiate a considerable long-term recurrence-free-survival in patients treated with single-agent ifosfamide radiochemotherapy. Despite of the limitations of the retrospective comparison of different patient groups and the small case numbers, the data strongly suggest a better outcome of radiochemotherapy in combination with ifosfamide compared to radiotherapy alone and radiotherapy in combination with other radiosensitizers. The described treatment protocol should be tested in a greater patient population in order to generate more reliable data.
Conflict of Interest Statement
The authors declare that they have no competing interests.
- Swallow CJ, Catton CN: Local management of adult soft tissue sarcomas. Semin Oncol 2007, 34: 256-269. 10.1053/j.seminoncol.2007.03.008View ArticlePubMedGoogle Scholar
- Hartmann JT: Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines. Anticancer Drugs 2007, 18: 245-254. 10.1097/CAD.0b013e3280124e41View ArticlePubMedGoogle Scholar
- Kaushal A, Citrin D: The role of radiation therapy in the management of sarcomas. Surg Clin North Am 2008, 88: 629-646. viii 10.1016/j.suc.2008.03.005PubMed CentralView ArticlePubMedGoogle Scholar
- Thornton K: Chemotherapeutic management of soft tissue sarcoma. Surg Clin North Am 2008, 88: 647-660. viii 10.1016/j.suc.2008.03.004View ArticlePubMedGoogle Scholar
- Raut CP, Pisters PW: Retroperitoneal sarcomas: Combined-modality treatment approaches. J Surg Oncol 2006, 94: 81-87. 10.1002/jso.20543View ArticlePubMedGoogle Scholar
- Kepka L, DeLaney TF, Suit HD, Goldberg SI: Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2005, 63: 852-859. 10.1016/j.ijrobp.2005.03.004View ArticlePubMedGoogle Scholar
- Goffman T, Tochner Z, Glatstein E: Primary treatment of large and massive adult sarcomas with iododeoxyuridine and aggressive hyperfractionated irradiation. Cancer 1991, 67: 572-576. 10.1002/1097-0142(19910201)67:3<572::AID-CNCR2820670308>3.0.CO;2-DView ArticlePubMedGoogle Scholar
- Maki RG: Role of chemotherapy in patients with soft tissue sarcomas. Expert Rev Anticancer Ther 2004, 4: 229-236. 10.1586/14737184.108.40.206View ArticlePubMedGoogle Scholar
- Anderson P, Aguilera D, Pearson M, Woo S: Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents. Cancer Control 2008, 15: 38-46.PubMedGoogle Scholar
- Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, et al.: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003, 348: 694-701. 10.1056/NEJMoa020890View ArticlePubMedGoogle Scholar
- Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, Evans HL: Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 225 patients. Cancer 2003, 97: 2530-2543. 10.1002/cncr.11365View ArticlePubMedGoogle Scholar
- Kinsella TJ, Glatstein E: Clinical experience with intravenous radiosensitizers in unresectable sarcomas. Cancer 1987, 59: 908-915. 10.1002/1097-0142(19870301)59:5<908::AID-CNCR2820590509>3.0.CO;2-ZView ArticlePubMedGoogle Scholar
- Rhomberg W, Hassenstein EO, Gefeller D: Radiotherapy vs. radiotherapy and razoxane in the treatment of soft tissue sarcomas: final results of a randomized study. Int J Radiat Oncol Biol Phys 1996, 36: 1077-1084. 10.1016/S0360-3016(96)00433-6View ArticlePubMedGoogle Scholar
- Toma S, Palumbo R, Sogno G, Canavese G, Barra S, Marziano C, Serrano J, Albanese E, Rosso R: Concomitant radiation-doxorubicin administration in locally advanced and/or metastatic soft tissue sarcomas: preliminary results. Anticancer Res 1991, 11: 2085-2089.PubMedGoogle Scholar
- Budach W, Reinelt A, Paulsen F, Belka C, Stueben G: Radiation therapy in combination with ifosfamide (IFO) in Human Soft Tissue Sarcoma (STS) Xenografts. Radiother Oncol 1998.,48(Suppl 1):
- Brodowicz T, Schwameis E, Widder J, Amann G, Wiltschke C, Dominkus M, Windhager R, Ritschl P, Potter R, Kotz R, Zielinski CC: Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial. Sarcoma 2000, 4: 151-160.PubMed CentralView ArticlePubMedGoogle Scholar
- Sauer R, Schuchardt U, Hohenberger W, Wittekind C, Papadopoulos T, Grabenbauer GG, Fietkau R: Neoadjuvant radiochemotherapy in soft tissue sarcomas. Optimization of local functional tumor control. Strahlenther Onkol 1999, 175: 259-266. 10.1007/BF02743576View ArticlePubMedGoogle Scholar
- Le QT, Fu KK, Kroll S, Fitts L, Massullo V, Ferrell L, Kaplan MJ, Phillips TL: Prognostic factors in adult soft-tissue sarcomas of the head and neck. Int J Radiat Oncol Biol Phys 1997, 37: 975-984. 10.1016/S0360-3016(97)00103-XView ArticlePubMedGoogle Scholar
- Willers H, Hug EB, Spiro IJ, Efird JT, Rosenberg AE, Wang CC: Adult soft tissue sarcomas of the head and neck treated by radiation and surgery or radiation alone: patterns of failure and prognostic factors. Int J Radiat Oncol Biol Phys 1995, 33: 585-593. 10.1016/0360-3016(95)00256-XView ArticlePubMedGoogle Scholar
- Kepka L, Suit HD, Goldberg SI, Rosenberg AE, Gebhardt MC, Hornicek FJ, Delaney TF: Results of radiation therapy performed after unplanned surgery (without re-excision) for soft tissue sarcomas. J Surg Oncol 2005, 92: 39-45. 10.1002/jso.20351View ArticlePubMedGoogle Scholar
- Cheifetz R, Catton CN, Kandel R, O'Sullivan B, Couture J, Swallow CJ: Recent progress in the management of retroperitoneal sarcoma. Sarcoma 2001, 5: 17-26. 10.1080/13577140120048908PubMed CentralView ArticlePubMedGoogle Scholar
- Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M: A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008, 113: 573-581. 10.1002/cncr.23592View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.